(2R,3S,4S,5S,6R)-2-[(2R,3R,4R,5R)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,4S,5S,6R)-2-[(2R,3R,4R,5R)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₁₂H₂₂O₁₀
• 分子量: 326.3
• InChiKey: QCYFORVYEGIBQL-VBEOFISCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  169
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• [EN] CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY<br/>[FR] SYSTÈMES À BASE DE CONJUGUÉS POUR ADMINISTRATION CONTRÔLÉE DE MÉDICAMENTS
  申请人：SMARTCELLS INC

  公开号：WO2010088294A1

  公开（公告）日：2010-08-05

  Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.